Advertisement
Screener

10x Genomics, Inc. (TXG) Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

10x Genomics, Inc. Accounts Receivable

10x Genomics, Inc. (TXG) had Accounts Receivable of $47.55 million as of 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current

us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-07

  • 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $47.55M.
  • 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $39.03M.
  • 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $47.01M.
  • 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $43.78M.
Period endAccounts Receivable, after Allowance for Credit Loss, Current
2026-06-30$47.55M
10-Q · filed 2026-08-07
2026-03-31$39.03M
10-Q · filed 2026-05-08
2025-12-31$47.01M
10-Q · filed 2026-08-07
2025-09-30$43.78M
10-Q · filed 2025-11-07
2025-06-30$49.98M
10-Q · filed 2025-08-08
2025-03-31$52.55M
10-Q · filed 2025-05-09
2024-12-31$87.86M
10-K · filed 2026-02-13
2024-09-30$83.53M
10-Q · filed 2024-10-29
2024-06-30$91.18M
10-Q · filed 2024-08-08
2024-03-31$91.31M
10-Q · filed 2024-04-30
2023-12-31$114.83M
10-K · filed 2025-02-13
2023-09-30$103.85M
10-Q · filed 2023-11-03
2023-06-30$87.69M
10-Q · filed 2023-08-04
2023-03-31$77.94M
10-Q · filed 2023-05-04
2022-12-31$104.21M
10-K · filed 2024-02-15
2022-09-30$83.55M
10-Q · filed 2022-11-03
2022-06-30$76.20M
10-Q · filed 2022-08-09
2022-03-31$76.53M
10-Q · filed 2022-05-05
2021-12-31$85.25M
10-K · filed 2023-02-16
2021-09-30$78.43M
10-Q · filed 2021-11-05
2021-06-30$59.68M
10-Q · filed 2021-08-06
2021-03-31$57.41M
10-Q · filed 2021-05-07
2020-12-31$51.21M
10-K · filed 2022-02-18
2020-09-30$36.03M
10-Q · filed 2020-11-12
2020-06-30$22.73M
10-Q · filed 2020-08-12
2020-03-31$30.85M
10-Q · filed 2020-05-12
2019-12-31$33.37M
10-K · filed 2021-02-26
2019-09-30$26.15M
10-Q · filed 2019-11-12
2018-12-31$28.09M
10-K · filed 2020-02-27